Atara Biotherapeutics (ATRA) Other financing activities (2015 - 2025)
Atara Biotherapeutics' (ATRA) quarterly Other financing activities came in at $36000.0 in Q4 2025, down 69.23% YoY from $117000.0 in Q4 2024, and down 69.23% on a QoQ basis from $117000.0 in Q4 2024.
Atara Biotherapeutics (ATRA) Other financing activities (2015 - 2025) Analysis & Trends
Atara Biotherapeutics (ATRA) has 11 years of Other financing activities data on file, last reported at $36000.0 in Q4 2025.
- Quarterly Other financing activities fell 69.23% year-over-year to $36000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $153000.0 (down 33.48% YoY) and the FY2025 annual result came in at $35000.0, down 84.78% from the prior year.
- Other financing activities declined to $36000.0 in Q4 2025, from $117000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $5.2 million in Q3 2021 to a low of -$5.2 million in Q4 2021.
- A 5-year average of $3384.6 and a median of $36000.0 in 2025 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2021 — Other financing activities surged 1160.0% — and 2022, when it sank 129.96%.
- Tracing ATRA's Other financing activities over 5 years: stood at -$5.2 million in 2021, then jumped by 99.29% to -$37000.0 in 2022, then plunged by 1954.05% to -$760000.0 in 2023, then surged by 115.39% to $117000.0 in 2024, then tumbled by 69.23% to $36000.0 in 2025.
- The last three Other financing activities figures came in at $36000.0 (Q4 2025), $117000.0 (Q4 2024), and $113000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 36,000.00 |
| Dec 31, 2025 | 36,000.00 |
| Dec 31, 2024 | 117,000.00 |
| Dec 31, 2024 | 117,000.00 |
| Jun 30, 2024 | 113,000.00 |
| Jun 30, 2024 | 113,000.00 |
| Sep 30, 2023 | -760,000.00 |
| Sep 30, 2023 | -760,000.00 |
| Jun 30, 2023 | 747,000.00 |
| Jun 30, 2023 | 747,000.00 |
| Dec 31, 2022 | -37,000.00 |
| Dec 31, 2022 | -37,000.00 |
| Sep 30, 2022 | -1.56 Mn |
| Sep 30, 2022 | -1.56 Mn |
| Jun 30, 2022 | 1.51 Mn |
| Jun 30, 2022 | 1.51 Mn |
| Mar 31, 2022 | -104,000.00 |
| Mar 31, 2022 | -104,000.00 |
| Dec 31, 2021 | -5.21 Mn |
| Dec 31, 2021 | -5.21 Mn |